The efficacy, safety and tolerability of canakinumab in the treatment of familial Mediterranean fever : a systematic review of the literature
Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%-10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1[beta], has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.
© 2020 Kacar et al.
2020
2021-04-08 14:43:47
1033
familial Mediterranean fever -- therapy -- review, monoclonal antibodies, canakinumab, anti-IL1 therapy
družinska mediteranska vročica -- terapija -- pregled literature, monoklonska protitelesa, canakinumab, anti-IL1 terapija
Dove Press
Mark
Kačar
70
Sinisa
Savic
70
Jeroen CH
van der Hilst
70
UDK
4
577.2
ISSN pri članku
9
1178-7031
DOI
15
10.2147/JIR.S206204
COBISS_ID
3
58075139
RAZ_Kacar_Mark_i2020.pdf
474846
Predstavitvena datoteka
2021-05-03 13:35:41
0
Izvorni URL
2021-05-03 13:02:52